GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » PetVivo Holdings Inc (OTCPK:PETVW) » Definitions » Risk Assessment

PetVivo Holdings (PetVivo Holdings) Risk Assessment


View and export this data going back to 2021. Start your Free Trial

What is PetVivo Holdings Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of PetVivo Holdings is: No Data: Cannot be evaluated.


Competitive Comparison of PetVivo Holdings's Risk Assessment

For the Medical Devices subindustry, PetVivo Holdings's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PetVivo Holdings's Risk Assessment Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, PetVivo Holdings's Risk Assessment distribution charts can be found below:

* The bar in red indicates where PetVivo Holdings's Risk Assessment falls into.



PetVivo Holdings  (OTCPK:PETVW) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.


PetVivo Holdings Risk Assessment Related Terms

Thank you for viewing the detailed overview of PetVivo Holdings's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.


PetVivo Holdings (PetVivo Holdings) Business Description

Traded in Other Exchanges
Address
5251 Edina Industrial Boulevard, Edina, MN, USA, 55439
PetVivo Holdings Inc is an emerging biomedical device company. The group is focused on the manufacturing, commercialization, and licensing of medical devices and therapeutics for companion animals. A key strategy of the company is to leverage human therapies for the treatment of companion animals cost-effectively and in a timely manner. The accelerated timeline to revenues for veterinary medical devices is a key component of this strategy, which enter the market much earlier than pharmaceuticals and biologics. The product pipeline includes approximately seventeen products intended to treat animals and people. Its patent protection extends to biomaterials, products, production processes, and methods of use provided by the company's portfolio of nineteen patents.